Cronos Group Stock Price, News & Analysis
Company Description
Cronos Group Inc. (NASDAQ: CRON, TSX: CRON) is a cannabinoid-focused company in the medicinal and botanical manufacturing industry. Headquartered in Toronto, Canada, and incorporated in British Columbia, Canada, Cronos describes itself as an innovative global cannabinoid company committed to advancing cannabis research, technology and product development. The company is building a portfolio of cannabis brands that serve both medical and adult-use markets in multiple countries.
Cronos’ international brand portfolio includes Spinach®, PEACE NATURALS® and Lord Jones®. According to company disclosures and recent news releases, these brands span recreational cannabis products in Canada and medical cannabis offerings in markets such as Israel and several European and other international jurisdictions. Cronos has also highlighted a focus on what it calls a “borderless product” strategy, using its cannabis genetics, research and product development capabilities to support growth across regions.
Business focus and brand portfolio
In Canada, Cronos operates in the adult-use cannabis market primarily through its Spinach® and Lord Jones® brands. Company news reports indicate that Spinach® products participate in categories such as flower, vapes, pre-rolls and edibles, with SOURZ by Spinach® gummies described as a key driver of the brand’s edible performance. Lord Jones® is positioned by Cronos as a premium brand, with products such as chocolate edibles and live resin-infused pre-rolls highlighted in recent Canadian launches.
In Israel and other medical markets, Cronos emphasizes its PEACE NATURALS® brand. Company communications state that PEACE NATURALS® is a medical cannabis brand that has been launched in multiple countries. Cronos reports that PEACE NATURALS® products are available to patients in markets including Canada, Israel, Germany, the United Kingdom, Australia, Switzerland and Malta, reflecting the company’s focus on international medical cannabis distribution.
International expansion and partnerships
Cronos describes itself as pursuing global growth, with a particular emphasis on Europe and other emerging medical cannabis markets. In a news release regarding Switzerland, the company announced that it is expanding distribution of PEACE NATURALS® medical cannabis in the Swiss market through a partnership with Dascoli Pharma AG, a Swiss-based company specializing in the supply and distribution of medical cannabis and healthcare training. Under that agreement, Cronos supplies PEACE NATURALS®-branded cannabis flower to Dascoli for distribution across its medical network in Switzerland.
The company has also announced a definitive agreement for one of its wholly owned subsidiaries to acquire all of the outstanding shares of CanAdelaar B.V., described as the largest cannabis company operating within the Netherlands’ adult-use cannabis pilot program known as the Wietexperiment. CanAdelaar is headquartered in Voorne aan Zee, Netherlands, and operates a large greenhouse cultivation, processing, production and packaging facility serving coffee shops in the participating Dutch municipalities. Cronos states that this transaction is intended to establish a strategic footprint in Europe’s adult-use cannabis market and to support its borderless product strategy, subject to customary closing conditions and regulatory clearances in the Netherlands.
Operations, cultivation and manufacturing
Within its broader manufacturing and cultivation footprint, Cronos highlights its investment in Cronos Growing Company Inc. (Cronos GrowCo), a cultivation operation in which Cronos obtained majority control of the board of directors and began consolidating results. Company filings and earnings releases describe the expansion of Cronos GrowCo’s cultivation operations and indicate that this expansion is intended to provide additional cannabis flower supply for both international markets and the domestic Canadian market.
Through its brands and partnerships, Cronos participates in product formats that include cannabis flower and extracts. In the Netherlands’ Wietexperiment, CanAdelaar sells products such as flower, pre-rolls, hash and edibles under the CanAdelaar Original Grow (C.O.G.) brand. In Switzerland and other medical markets, PEACE NATURALS®-branded flower is supplied to distribution partners. In Canada, Cronos has highlighted Spinach® and Lord Jones® products in categories such as gummies, vapes, chocolate edibles, hash-infused pre-rolls and live resin-infused pre-rolls.
Geographic footprint
According to Cronos’ news releases, the company’s activities span several regions:
- Canada: Adult-use cannabis products under Spinach® and Lord Jones® brands, as well as cultivation operations through Cronos GrowCo.
- Israel: Medical cannabis market served by the PEACE NATURALS® brand, where Cronos reports strong demand and significant brand presence.
- Europe and other international markets: Medical cannabis distribution under PEACE NATURALS® in Germany, the UK, Australia, Switzerland and Malta, and a planned adult-use presence in the Netherlands through the proposed acquisition of CanAdelaar.
In addition, Cronos has made a financial investment in High Tide Inc., which operates the Canna Cabana retail chain in Canada. The company describes this as a junior secured convertible loan and notes that it also received share purchase warrants as part of the transaction. Cronos has characterized this investment as supporting a competitive retail environment for cannabis producers and retailers in Canada.
Regulatory and public company status
Cronos Group Inc. is a reporting issuer in both Canada and the United States. The company files reports with the U.S. Securities and Exchange Commission under Commission File Number 001-38403 and has filed multiple current reports on Form 8-K describing matters such as quarterly financial results, annual meeting voting outcomes and changes in certain officers. These filings confirm that Cronos remains an active public company with ongoing regulatory reporting obligations.
Strategic themes
Across its public communications, Cronos emphasizes several recurring themes:
- A focus on cannabis research, technology and product development as a way to build intellectual property in cannabinoids.
- Development of an iconic brand portfolio spanning adult-use and medical markets, including Spinach®, PEACE NATURALS® and Lord Jones®.
- Pursuit of a borderless product strategy, using genetics and product development capabilities to support offerings across multiple countries, subject to local regulations.
- Expansion of its international footprint through partnerships, brand launches in new medical markets and proposed acquisitions such as CanAdelaar in the Netherlands.
According to its earnings releases, Cronos also highlights its cash and short-term investments and describes its balance sheet as debt-free, which it views as providing flexibility to pursue global expansion and investments.
Frequently Asked Questions about Cronos Group Inc.
The following FAQs summarize key aspects of Cronos based on the company’s own descriptions and public filings.
Stock Performance
Cronos Group (CRON) stock last traded at $2.62, up 0.98% from the previous close. Over the past 12 months, the stock has gained 43.2%. At a market capitalization of $978.0M, CRON is classified as a small-cap stock with approximately 379.1M shares outstanding.
Latest News
Cronos Group has 10 recent news articles. Of the recent coverage, 7 articles coincided with positive price movement and 2 with negative movement. Key topics include conferences, acquisition. View all CRON news →
SEC Filings
Cronos Group has filed 5 recent SEC filings, including 5 Form 4. The most recent filing was submitted on March 20, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all CRON SEC filings →
Financial Highlights
Cronos Group generated $146.6M in revenue over the trailing twelve months, retaining a 42.8% gross margin, operating income reached -$17.4M (-11.9% operating margin), and net income was -$9.4M, reflecting a -6.4% net profit margin. Diluted earnings per share stood at $-0.02. The company generated $25.9M in operating cash flow. With a current ratio of 19.59, the balance sheet reflects a strong liquidity position.
Upcoming Events
National product availability
Contingent earnout payment
Cronos Group has 2 upcoming scheduled events. The next event, "National product availability", is scheduled for April 1, 2026 (in 6 days). 1 of the upcoming events are financial in nature, such as earnings calls or quarterly results. Investors can track these dates to stay informed about potential catalysts that may affect the CRON stock price.
Short Interest History
Short interest in Cronos Group (CRON) currently stands at 3.5 million shares, down 22.9% from the previous reporting period, representing 1.8% of the float. Over the past 12 months, short interest has decreased by 17.3%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Cronos Group (CRON) currently stands at 2.2 days, down 37.5% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The days to cover has decreased 35.4% over the past year, suggesting improved liquidity for short covering. The ratio has shown significant volatility over the period, ranging from 1.0 to 3.5 days.
CRON Company Profile & Sector Positioning
Cronos Group (CRON) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Medicinal Chemicals & Botanical Products sector and is listed on the NASDAQ.
Investors comparing CRON often look at related companies in the same sector, including TILRAY BRANDS INC (TLRY), Dynavax Technolo (DVAX), Evotec Ag (EVO), Pacira Biosciences Inc (PCRX), and Akebia Therapeut (AKBA). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate CRON's relative position within its industry.